Ajay Pandita

Dr. Ajay Pandita

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2013 in Oncogenesis
Verified
Journal Article
Open access
PDF file
LHL-Y Huw
L-Y Huw
COC O'BRien
C O'BRien
APAjay Pandita
Ajay Pandita
SMS Mohan
S Mohan
JSJ M Spoerke
J M Spoerke
MLM R Lackner
M R Lackner
Agents targeting the PI3K/mTOR signaling axis have shown promise in early-phase clinical trials and are currently being studied in later stages of clinical development in multiple indications. Experience with other targeted agents suggests that clinical responses may be short-lived because of acquired resistance to therapy. Here, we report preclinical modeling of acquired resistance in a HER2-positive, PIK3CA mutant breast cancer cell line, KPL-4. We identified a heretofore-unreported mechanism of resistance, specifically high-level amplification of the mutant allele of PIK3CA, which resulted in a marked upregulation of PI3K signaling, enabling resistant cells to regain proliferative capacity at clinically relevant concentrations of the PI3K inhibitor, GDC-0941. We show that knockdown of the amplified PIK3CA mutant allele in these cells by small interfering RNA restored pathway signaling and sensitivity to PI3K inhibition at levels comparable to parental cells. These novel preclinical findings suggest that, in addition to assessment of other previously reported mechanisms of resistance, evaluation of PI3K copy number variation should be integrated into the exploratory analysis of biopsies obtained at disease progression.

1 September 2011 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
SLSi Tuen Lee-Hoeflich
Si Tuen Lee-Hoeflich
TPThinh Q. Pham
Thinh Q. Pham
DDDon Dowbenko
Don Dowbenko
XMXander Munroe
Xander Munroe
JLJames Lee
James Lee
HSHoward M. Stern
Howard M. Stern
The HER2 oncogene is overexpressed or amplified in 20% of breast cancers. HER2-positive cancer historically portends a poor prognosis, but the HER2-targeted therapy trastuzumab mitigates this otherwise ominous distinction. Nevertheless, some patients suffer disease recurrence despite trastuzumab, and metastatic disease remains largely incurable due to innate and acquired resistance. Thus, understanding trastuzumab resistance remains an unmet medical need. Through RNA interference screening, we discovered that knockdown of the serine/threonine phosphatase PPM1H confers trastuzumab resistance via reduction in protein levels of the tumor suppressor p27. PPM1H dephosphorylates p27 at threonine 187, thus removing a signal for proteasomal degradation. We further determined that patients whose tumors express low levels of PPM1H trend towards worse clinical outcome on trastuzumab. Identifying PPM1H as a novel p27 phosphatase reveals new insight into how cancer cells destabilize a well-recognized tumor suppressor. Furthermore, low PPM1H expression may identify a subset of HER2-positive tumors that are harder to treat. Significance: PPM1H is identified as a phosphatase impacting p27 stability. Low expression of PPM1H may be associated with poor outcome in breast cancer. Cancer Discovery; 1(4); 326–337. ©2011 AACR. Read the Commentary on this article by Aceto and Bentires-Alj, p. 285 This article is highlighted in the In This Issue feature, p. 275

5 May 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JMJoydeep Mukherjee
Joydeep Mukherjee
APAjay Pandita
Ajay Pandita
KCKamalakar Chatla
Kamalakar Chatla
TJTor-Christian Johannessen
Tor-Christian Johannessen
SOShigeo Ohba
Shigeo Ohba
RPRussell Pieper
Russell Pieper
Tumor cells using the ALT mechanism to maintain telomeres are uniquely sensitive to PARP inhibitor–induced lethal chromosomal fusion.

1 January 1997 in Cytogenetic and Genome Research
Verified
Journal Article
Closed access
PDF file
RGRoseline Godbout
Roseline Godbout
APAjay Pandita
Ajay Pandita
BBB. Beatty
B. Beatty
WBW. Bie
W. Bie
JSJeremy Andrew Squire
Jeremy Andrew Squire
The four mitochondrial ATP synthase α-subunit (ATP5A) genes map to chromosomes 2, 9, 16, and 18. In this study we have refined the localization of two of these genes by fluorescence in situ hybridization (FISH) to metaphase spreads, and further characterised the involvement of ATP5A in the amplification process in the retinoblastoma cell line Y79. Comparative genomic hybridization (CGH) analysis of Y79 indicated that gene amplification was present on both the short arm of chromosome 2 and the long arm of chromosome 18. FISH indicated that the functional ATP5A gene mapped to 18q12→q21 the same band location identified by CGH analysis of Y79. An ATP5A pseudogene (ATP5AP1) maps to 9p12. Gains in chromosomal material at 18q12→q21 likely involve hybridization to amplified copies of the ATP5A gene while gains at 2p24 represent hybridization to the MYCN and DDX1 genes, also amplified in Y79.

27 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
SASaloni Andhari
Saloni Andhari
JFJaspreet Farmaha
Jaspreet Farmaha
AVASHUTOSH VASHISHT
ASHUTOSH VASHISHT
VVVishakha Vashisht
Vishakha Vashisht
JWJana Woodall
Jana Woodall
RKRavindra Kolhe
Ravindra Kolhe
Circulating tumor cells (CTCs) are shed from the primary tumor into the bloodstream and represent dynamic molecular biomarkers for monitoring the progression of cancer. While profiling tumor tissues with over expression of cell surface markers, such as PD-L1 or HER2, is standard in guiding therapy, tissue samples are often inaccessible and inadequate, especially post-surgery or in cases of recurrence. Emerging clinical evidence indicates that CTC counts and biomarker surface expression can predict prognosis and therapeutic resistance more accurately than imaging or tissue-based approaches. Recent advancements in the CTC detection methods, based on physical properties or surface markers (e.g., EpCAM), coupled with next-generation sequencing (NGS) have enabled the isolation of these rare cells and their molecular characterization. Consequently, CTCs provide a real-time alternative, enabling repeated, longitudinal assessment of tumor phenotype and therapeutic response. This review emphasizes the translational potential of surface protein biomarkers on CTCs for profiling, namely PD-L1, HER2, and EGFR, as a clinically actionable approach to stratify patients, guide immunotherapy decisions, and monitor minimal residual disease (MRD), especially when longitudinal tissue biopsies are not feasible.

3 April 2023
Verified
Other
Open access
SLSi Tuen Lee-Hoeflich
Si Tuen Lee-Hoeflich
TPThinh Q. Pham
Thinh Q. Pham
DDDon Dowbenko
Don Dowbenko
XMXander Munroe
Xander Munroe
JLJames Lee
James Lee
HSHoward M. Stern
Howard M. Stern